经颈内静脉完全植入式输液港在乳腺癌化疗中的应用

目的总结经颈内静脉放置全植入式输液港(TIVAP)作为乳腺癌化疗静脉输液通路的使用经验。方法对2013年6月~2015年12月486例行输液港植入术的乳腺癌化疗患者进行回顾性研究,观察其术后及远期并发症。结果全部病例均在术中成功完成输液港植入。l例出现心悸不适,2例穿刺点周围局部血肿,1例囊袋内港体周围血肿,2例气胸,3例导管相关性感染,2例导管堵塞,1例导管断裂。至末次随访,65例带管时间4~30个月,中位带管时间15个月。本组未出现导丝断裂、pinch-off综合征等严重并发症。结论经颈内静脉放置全植入式输液港是乳腺癌化疗安全、有效的输液途径。

Implantation of totally implantable venous access port via internal jugular vein in chemotherapy for breast cancer

Objective To summarize up the effect of totally implantable venous access ports (TIVAP) implanted via internal jugular vein on chemotherapy for breast cancers. Methods A retrospective review was conducted on 96 patients undergoing a TIVAP implantation for breast cancer chemotherapy at our hospital from June 2013 to December 2015. Surgical and long-term complications were analyzed. Results All TIVAPs were implanted successfully. There were one case of cardiac arrhythmia, one case of hematoma, two case of pneumothorax, two cases of catheter occlusion, three case of catheter-related infection and one case of catheter rupture. The patients were followed up for a median of 15 months (4-30 months). TIVAP worked well without leakage, pneumothorax, infection, or pinch-off syndrome. Conclusion Implanting totally implantable venous access port via the internal jugular vein is feasible and safe in patients with breast cancer.